胶质母细胞瘤介入性临床试验现状与展望:基于ClinicalTrials.gov的分析
结果显示学术中心发起试验占56.9%,工业界为主要资金源占44.4%,2005至2015年新启动试验呈上升趋势主要因II期试验增加而III期减少,91.2%的试验评估系统性治疗,放疗、手术和影像学试验罕见。
要点
- 胶质母细胞瘤试验以系统性治疗为主(91.2%),放疗和手术试验占比低。
- 学术中心发起试验占56.9%,工业界资助占44.4%,III期试验数量呈下降趋势。
- 共识别100种分子实体或生物制剂,其中60%为中枢神经系统恶性肿瘤专门设计。
核心结论
- 当前胶质母细胞瘤研究主要由工业界和学术肿瘤内科/神经肿瘤科医生驱动,多数试验评估系统性治疗,极少进入III期,放疗、手术和影像学试验在试验组合中代表性不足,需要优化研究布局。
主要发现
- 学术中心(研究者发起试验)作为主要申办方占56.9%,工业界占25.9%;工业界为主要资金支持来源占44.4%,学术资金支持占25%。
- 2005年至2015年间新启动试验数量呈积极趋势,主要因II期试验增加,而III期试验呈消极趋势。
- 绝大多数试验(91.2%)评估不同形式的系统性治疗,共识别100种不同分子实体或生物制剂,其中60%涉及专门为中枢神经系统恶性肿瘤设计的药物。
- 专门针对放疗、手术、影像学及其他治疗或诊断方法的试验罕见。
临床怎么用
- 提示临床医生和研究者关注胶质母细胞瘤试验中放疗、手术和影像学研究的不足,在试验设计和 funding 申请中考虑填补这些空白。
局限性
- 研究仅基于2016年2月19日ClinicalTrials.gov的注册记录,可能未涵盖其他注册平台或未注册试验,且为回顾性分类分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The records of 208.777 (100%) clinical trials registered at ClinicalTrials.gov were downloaded on the 19th of February 2016. Phase II and III trials including patients with glioblastoma were selected for further classification and analysis. Based on the disease settings, trials were classified into three groups: newly diagnosed glioblastoma, recurrent disease and trials with no differentiation according to disease setting. Furthermore, we categorized trials according to the experimental interventions, the primary sponsor, the source of financial support and trial design elements. Trends were evaluated using the autoregressive integrated moving average model. Two hundred sixteen (0.1%) trials were selected for further analysis. Academic centers (investigator initiated trials) were recorded as primary sponsors in 56.9% of trials, followed by industry 25.9%. Industry was the leading source of monetary support for the selected trials in 44.4%, followed by 25% of trials with primarily academic financial support. The number of newly initiated trials between 2005 and 2015 shows a positive trend, mainly through an increase in phase II trials, whereas phase III trials show a negative trend. The vast majority of trials evaluate forms of different systemic treatments (91.2%). In total, one hundred different molecular entities or biologicals were identified. Of those, 60% were involving drugs specifically designed for central nervous system malignancies. Trials that specifically address radiotherapy, surgery, imaging and other therapeutic or diagnostic methods appear to be rare. Current research in glioblastoma is mainly driven or sponsored by industry, academic medical oncologists and neuro-oncologists, with the majority of trials evaluating forms of systemic therapies. Few trials reach phase III. Imaging, radiation therapy and surgical procedures are underrepresented in current trials portfolios. Optimization in research portfolio for glioblastoma is needed.
引用
- Cihoric N, Tsikkinis A, Minniti G, et al. Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov. Radiat Oncol. 2017. PMID: 28049492. doi:10.1186/s13014-016-0740-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。